title: Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
abstract: OBJECTIVE
  To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 1 and 11 years of age with gastroesophageal reflux disease (GERD).
  
  
  METHODS
  In a multicenter, open-label trial of pediatric patients with symptomatic GERD, children were assigned, based on their weight, to receive lansoprazole 15 mg (patients weighing < or = 30 kg) or lansoprazole 30 mg (patients weighing > 30 kg) once daily. The effects of lansoprazole on 24-hour median intragastric pH, the percentages of time intragastric pH was above 3 and 4, and pharmacokinetic parameters were assessed at the day-5 visit and compared to baseline.
  
  
  RESULTS
  Sixty-six children were enrolled in the study. Mean lansoprazole C(max) values of 790.9 ng/mL and 898.5 ng/mL and T(max) values of 1.5 hours and 1.7 hours were observed in the < or = 30 kg and the > 30 kg body weight treatment groups, respectively. AUC0-24 values of 1707 ng x h/mL and 1883 ng x h/mL and T1/2 values of 0.68 hours and 0.71 hours were observed in the < or = 30 kg and > 30 kg lansoprazole body weight treatment groups, respectively. There was no statistical significant difference in AUC0-24 between the two groups (P = 0.2571). After 5 days of treatment lansoprazole produced significant increases in patients' 24-hour mean intragastric pH and the percentages of time intragastric pH was above 3 and 4 compared to baseline.
  
  
  CONCLUSIONS
  The observed pharmacokinetic properties of lansoprazole in children between 1 and 11 years of age with GERD were similar to those previously observed in healthy adult subjects. Lansoprazole significantly increased the mean 24-hour intragastric pH and the percentages of time intragastric pH was above 3 and 4 when children were dosed with either 15 or 30 mg according to body weight.
authors.affiliation: Division of Pediatric GI/Nutrition, University of South Alabama, Mobile, Alabama 36604-3273, USA.
authors.forename: David
authors.initials: D
authors.lastname: Gremse
authors.forename: Harland
authors.initials: H
authors.lastname: Winter
authors.forename: Vasundhara
authors.initials: V
authors.lastname: Tolia
authors.forename: Thirumazhisai
authors.initials: T
authors.lastname: Gunasekaran
authors.forename: Wei-Jian
authors.initials: WJ
authors.lastname: Pan
authors.forename: Michael
authors.initials: M
authors.lastname: Karol
authors.forename: Yi-Lin
authors.initials: YL
authors.lastname: Chiu
authors.forename: Betsy
authors.initials: B
authors.lastname: Pilmer
authors.forename: Linda
authors.initials: L
authors.lastname: Book
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D019540:Area Under Curve; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005745:Gastric Acidity Determination; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007223:Infant; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000494:pharmacology*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole